Feasibility of Internet-delivered CBT for Adolescents With Depression

Major Depressive Disorder Clinical Trial

Official title:

Feasibility of Internet-delivered Cognitive Behavior Therapy for Adolescents With Mild to Moderate Depression: A Randomized Pilot Study Comparing Therapist-guided vs. Self-guided ICBT vs. Treatment as Usual

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04117789
• Other study ID #: 2019-03235
• Status: Completed
• Phase: N/A
• Start date: October 14, 2019
• Est. completion date: October 21, 2020

Study information

• Verified date: October 2020
• Source: Karolinska Institutet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prior to a properly powered randomized controlled study, evaluating efficacy and cost-effectiveness of ICBT, we will conduct a pilot study to investigate if the trial design is feasible, if therapist-guided and self-guided internet-delivered cognitive behavioral therapy (ICBT) is acceptable for adolescents with depression and to provide preliminary clinical efficacy data.

Description:

A single-blind parallel-group pilot randomised controlled feasibility trial with the overall aim to develop two internet-delivered cognitive behaviour therapy interventions, therapist-guided and self-guided, for adolescents with mild to moderate Major Depressive Disorder (MDD) and their primary caregivers.

Patients can be either referred or self-referred. All potential participants are initially screened via telephone. This is followed by a face-to-face inclusion assessment. Participants who are eligible and have consented will be randomized into one of three trial arms; therapist-guided ICBT, self-guided ICBT or TAU. In the experimental arms, participants, e.g. the adolescent and at least one caregiver, either receive 10 weeks of therapist-guided or self-guided internet-delivered behavioural activation (BA). In the control arm, participants receive treatment as usual within the Child and Adolescent Mental Health Services (CAMHS) or primary care clinics. The primary endpoint will be at 3-month follow-up.

The primary objective is to evaluate the feasibility of the study design and trial procedures, including recruitment, withdrawal, drop out and attrition rates. The secondary objective is to (a) evaluate the acceptability of the ICBT interventions in regard to treatment satisfaction, credibility, reported adverse events, and program use, (b) to provide preliminary clinical efficacy data, and (c) to gather qualitative information on the experience of undergoing ICBT for depression from the perspective of adolescent patients, their caregivers and potential areas for improvement of future ICBT interventions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: October 21, 2020
• Est. primary completion date: October 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years to 17 Years

Eligibility

Inclusion Criteria:

• Primary diagnosis of mild to moderate MDD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th ed.

• Willing to be randomized to either of the three treatment arms.

• Basic proficiency in Swedish, both adolescent and participating care-giver

• Regular access to a desktop or laptop computer connected to the internet, as well as a mobile phone to receive sms (one of each is enough per family).

• Stable medication with antidepressants, central stimulants and neuroleptics at least 6 weeks prior to inclusion.

• A minimum of one caregiver that is able to co-participate in the treatment.

Exclusion Criteria:

• Immediate risk to self or others, requiring urgent medical attention, such as suicidality, or repeated self-injurious behaviour.

• Other severe psychiatric disorders requiring other actions at first hand (e.g. diagnosis of organic brain disorder, intellectual disability, psychosis, bipolar disorder, eating disorder, or alcohol/substance dependence;

• Current social problems requiring other actions at first hand (e.g. bullying in school, abuse and/or neglect in the family; high and prolonged absence from school).

• Previous CBT for MDD within the last 12 months prior to assessment, for a minimum of 3 sessions other than psychoeducation with a qualified therapist within the 12 months prior to assessment.

• Current use of benzodiazepines.

• An ongoing psychological treatment for any other psychiatric disorder.

Related Conditions & MeSH terms

• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Behavioral:
• Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents
Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
• Self-guided internet-delivered cognitive behavior therapy for depression in adolescents
Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.

Other:
• Treatment as usual
Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.

Locations

Country	Name	City	State
Sweden	Child and Adolescent Psychiatry Research Center	Stockholm

Sponsors (2)

Lead Sponsor	Collaborator
Karolinska Institutet	Stockholm County Council, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Behavioral activation of Depression Scale - short form (BADS-S)	The BADS-S is designed to track changes in proposed mediators of behavioral activation, e.g. activation and avoidance. Total range is from 0-54 with higher values indicating higher degree of activation and lower degree of avoidance.; Changes during treatment in proposed mediators of behavioral activation on the BADS-S will be reported for the ICBT interventions.	weekly during treatment (week 1 to week 10)
Other	Trimbos Questionnaire for Costs associated with Psychiatric Illness (TiC-P)	The TiC-P assess healthcare and societal resource use, including for example items on healthcare resource use, medications, school absenteeism, and parental productivity loss. In the present study no health economic evaluations will be conducted. Rather this instrument is included to gain feasibility data in preparation of a planned larger randomized controlled study. Therefore, no data on TiC-P will be reported in this trial.	week 0, week 10, at 3 months follow-up
Primary	Children's Depression Rating Scale - Revised (CDRS-R)	CDRS-R is a semi-structured clinician interview, assessing level of depressive symptomatology. Total range is 17-113, with higher values representing a worse outcome. Change from baseline in depressive symptom severity on the CDRS-R at end of treatment, and at 3-months follow-up will be reported. Primary endpoint is 3 months follow-up.	week 0, week 10, at 3 months follow-up
Secondary	Treatment credibility and expectancy scale - adolescent and parent version	This scale consists of four qualitative questions about treatment credibility, asking how well the treatment suits adolescents with depression, how much they believe this treatment will help him/her, if and to what extent they would recommend this treatment to a friend with depression and how much improvement they expect from the treatment. Total range is 4-20, with higher values representing higher credibility. Mean in total treatment credibility score on the "Treatment credibility scale" for each treatment group at week 3 will be reported.	week 3
Secondary	The Client Satisfaction Questionnaire-8 (CSQ-8) - adolescent and parent version	The CSQ-8 is an 8-item self-rated 4-point scale, measuring different aspects of satisfaction with treatment, e.g. perception of quality of treatment, if the treatment adequately addressed their needs and overall satisfaction. Total range is 8 to 32, with higher values indicating higher satisfaction. Mean in total satisfaction scores on the CSQ-8 for each treatment group at end of treatment and at follow-up will be reported.	week 10, at 3 months follow-up
Secondary	Need for further treatment - adolescent and parent version	Investigate whether the participant considers her/himself in need of further treatment for her/his depression.	week 10, at 3 months follow-up
Secondary	Negative Effects Questionnaire (NEQ-20) - adolescent and parent version	NEQ-20 investigate participants' negative effects of psychological treatments. Total range is 0-80, with higher values representing a worse outcome.; Descriptive data in negative effects of treatments on the NEQ-20 will be reported for participants randomized to either of the ICBT interventions at mid treatment, after end of treatment and at 3 months follow-up.	week 5, week 10, at 3 months-follow up
Secondary	Treatment completion	Adherence in terms of numbers of completed chapters for patients and their parents respectively in the ICBT interventions will be reported after 10 weeks. This data will be collected from the IT platform that delivers the ICBT interventions.	week 10
Secondary	Therapist time	Total therapist time per patient an week will be reported for the ICBT interventions at the end of the pilot study. This data will be collected from the IT platform that delivers the ICBT interventions.	week 1 to week 10
Secondary	Clinical Global Impression Scale - Severity (CGI-S)	CGI-S is developed to assess how mentally ill a specific patient compared to a particular patient population (e.g. with major depressive disorder) at a certain time.; It consists of a single item rated on a seven-point scale ranging from 1="no symptoms" to 7="extreme symptoms". Change from baseline in global severity of depressive symptoms on the CGI-S at end of treatment, and at 3 months follow-up will be reported.	week 0, week 10, at 3 months follow-up
Secondary	Clinical Global Impression - Improvement (CGI-I)	CGI-I is developed to assess improvement of psychiatric symptoms for a specific patient compared to baseline. It consists of a single item rated on a seven-point scale ranging from 1="very much improved" to 7="very much worse". Change from baseline in global improvement of depressive symptoms to end of treatment and at 3 months follow-up on the CGI-I will be reported.	week 10, at 3 months follow-up
Secondary	Children's global assessment scale (CGAS)	The CGAS is a single item 1-100 scale that integrates psychological, social, and academic functioning in children as a measure of psychiatric disturbance. Higher values represent a worse outcome. Change from baseline in global functioning CGAS to end of treatment and at 3 months follow-up will be reported.	week 0, week 10, at 3 months follow-up
Secondary	Short Mood and Feeling Questionnaire (SMFQ) - adolescent and parent version	The SMFQ is a 13-item self-reported measure of depressive symptoms. Total range is 0-26, with higher values representing a worse outcome. Change from baseline in adolescent- and parent-rated depressive symptoms on the SMFQ to week 10 and at 3 months follow-up, and weekly during treatment will be reported.; Additionally, for this trial, we have also added a 14th item, aimed to assess suicide risk. This item is not included in the total score.	week 0, weekly from week 1 to week 10, at 3 months follow-up
Secondary	The Revised Children's Anxiety and Depression Scale, short (RCADS-S) -adolescent and parent version	The RCADS-S, a shortened version of the Spence Child Anxiety Scale, is a child and parent self-report measure of anxiety- and depression-related psychopathology. Only the anxiety subscales are administered in this study, since depressive symptoms are measured thoroughly by other measures. Total range is 0-45, with higher values representing a worse outcome. Change from baseline in adolescent- and parent-rated depressive symptoms on the RCADS-S to end of treatment and at 3 months follow-up will be reported.	week 0, week 10, 3 months follow-up
Secondary	Affective Reactivity Index (ARI) - adolescent and parent version	ARI is a parent- and self-rated measure of irritability and impairment due to irritability. Total range is 0-12, with higher values representing a worse outcome. Change from baseline in adolescent- and parent-rated irritability and impairment due to irritability on the ARI to end of treatment, and at 3-months follow-up will be reported.	week 0, week 10, 3 months follow-up
Secondary	Insomnia Severity Index (ISI)	ISI, a brief screening measure of insomnia, a seven-item scale ranging from 0 to 28 points, with higher values representing a worse outcome. Change from baseline in sleep problems on ISI to end of treatment at 3 months follow-up will be reported.	week 0, week 10, at 3 months follow-up
Secondary	Work and Social Adjustment Scale, youth version (WSAS-Y) - adolescent and parent version	WSAS-Y is a parent- and adolescent-rated scale of impaired functioning in school, everyday life, friends and social life, recreation and hobbies and family and close relationships. The scale generates a global score ranging from 0 to 40, with higher scores indicating greater impairment. Change from baseline in adolescent- and parent rated impairment and functioning on the WSAS-Y will be reported at the end of treatment, and at 3 months follow-up.	week 0, week 10, 3 months follow-up
Secondary	Working Alliance Inventory, Short (WAI-S) - adolescent and parent version	The WAI-S is scale measuring the participants perceived working alliance with their therapist. Total range 12-84, with higher scores indicating a better working alliance. Descriptive data on participants' perceived working alliance with their therapist, or with the program for participants in the self-guided ICBT, on the WAI-S will be reported at end of treatment and at 3-months follow up.	week 10, 3 months follow-up
Secondary	Kidscreen-10 Index - adolescent and parent version	Kidscreen-10 assess the adolescents' general health-related quality of life. Total range from 10-50, with higher values indicating better health-related quality of life. Change from baseline in general health-related quality of life on the Kidscreen-10 will be reported at the end of treatment and at 3 months follow-up.	week 0, week 10, at 3 months follow-up